Erasca Inc. Common Stock vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Erasca Inc. Common Stock trades at $15.97 (market cap $5.40B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $121.85 (market cap $1.45B). The key difference: Erasca Inc. Common Stock is far larger — about 3.7× Direxion NASDAQ 100 Equal Weighted Index Shares's market cap, and Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Erasca Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Erasca Inc. Common Stock for 0 Days and Direxion NASDAQ 100 Equal Weighted Index Shares for 48 Days on average.
| ERAS | QQQE | |
|---|---|---|
Market Cap | $5.40B | $1.45B |
Volume | 9,533,185 | 323,568 |
Sector | Health | Broad Market / Factor |
52-Week High | $22.47 | $124.69 |
52-Week Low | $2.20 | $96.06 |
Typical Hold Time | 0 Days | 48 Days |
Enterprise Value | $5.18B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
QQQE trades at $121.92 with minimal daily movement (+0.02%). Technical indicators show a bullish trend with moving averages supporting upward momentum while oscillators remain neutral. The ETF's equal-weighted approach to NASDAQ-100 stocks provides diversification benefits, reducing technology concentration from 60% to 45% compared to market-cap weighted alternatives. Recent analysis suggests QQQE offers stronger fundamentals and technicals than QQQ for tactical positioning.
The outlook appears favorable with equal weighting providing balanced exposure to large-cap growth stocks. Key risks include technology sector volatility and market concentration concerns. Analyst sentiment leans positive for near-term performance, though investors should monitor broader market trends and sector rotations that could impact the NASDAQ-100 composition.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Erasca is a biotechnology company developing precision medicines for cancer. Its programs target genetic drivers of tumor growth.
Read more on ERAS →QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →